Alcon ALC 深 沪
已收盘 07-17 16:00:00 美东时间
70.26
-0.360
-0.51%
华盛通- 最 高71.49
- 今 开70.58
- 成交量 265.35万股
- 最 低 69.80
- 昨 收 70.62
- 总市值 3426.58万
- 52周最高 91.2506
- 市盈率 静 35.57
- 换手率 544.08%
- 52周最低 61.835
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 100.407
- 量 比 1.18
- 振 幅 2.39%
- 历史最低 37.8618
- 每 手 1
- 风险率 6.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
Alconix Corrects Details of Restricted Stock Compensation for Directors
ALCONIX Corporation ( ($JP:3036) ) has shared an announcement. Alconix Corporat...
07-16 09:22
RxSight appoints new CEO
RxSight (RXST) appointed Aziz Mottiwala as president and chief executive officer, effective July 20, 2026. Mottiwala succeeds Ron Kurtz, M.D., who will remain with the company as chief medical officer...
07-16 04:18
Mizuho Maintains Outperform on Alcon, Lowers Price Target to $80
Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $85 to $80.
07-16 02:21
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
WARSAW, Ind., July 14, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chintan Desai has been named president ...
07-14 19:00
Alcon collaborates with RxSight to develop adjustable PCIOLs
Alcon (ALC) and RxSight, Inc. (RXST) on Monday announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). Under the collaboration, the com...
07-07 04:51
RxSight, Alcon Partner on Light-Adjustable Cataract Lenses
RxSight ( ($RXST) ) has provided an announcement. On June 30, 2026, RxSight ent...
07-07 04:47
CORRECTED-RxSight says Q2 results hit by more widespread competitive trialing
CORRECTED-RxSight says Q2 results hit by more widespread competitive trialing Corrects throughout to report total revenue figures, instead of sales figures that the company includes as one part of total revenue; the story was previously corrected to remove an extraneous word in the headline Overview
07-07 04:35
Alcon And RxSight Announce A Non-Exclusive Collaboration To Jointly Develop Adjustable Presbyopia-Correcting Intraocular Lenses
Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaborati...
07-07 04:17
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
RxSight, Inc. reported preliminary Q2 2026 results, including total revenue of $32-$34M, $5-$7M from its collaboration with Alcon, and $27M in sales, driven by 24,917 LAL units and 11 LDD units sold. The company highlighted its next-gen Light Adjustable Lens platform with improved workflow and performance, and collaborations to develop adjustable IOLs. Despite commercial challenges, RxSight remains confident in its technology and pipeline, with u...
07-06 20:15
